세계의 길랭 바레 증후군 치료제 시장 보고서(2025년)

Guillain-Barre Syndrome Drugs Global Market Report 2025

US $ 4,490 ￦ 6,301,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,108,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,914,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

길랭 바레 증후군 치료제 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 연평균 성장률(CAGR) 7.9%로 17억 1,000만 달러에 달할 것으로 예상됩니다. 예측 기간의 성장은 길랭 바레 증후군(GBS) 발병률 증가, 인식 및 인정률 증가, 노인 인구 증가, 병원 약국 및 소매 약국의 역할 증가, 경구 및 비경구 의약품에 대한 수요 증가 등에 기인하는 것으로 추정됩니다. 예측 기간의 주요 동향으로는 새로운 치료법 개발, 진단 도구의 발전, 제약회사와 R&D 기관의 협력, 유전자 치료의 발전, 면역글로불린 정맥주사 치료의 발전 등을 꼽을 수 있습니다.

맞춤의료에 대한 수요가 급증할 것으로 예상되며, 길랭 바레 증후군 치료제 시장의 성장을 견인할 것으로 보입니다. 맞춤의료는 유전학, 생활습관 등 개인의 특성에 따라 치료를 맞춤화하여 효과를 최적화하고 부작용을 최소화하는 것입니다. 이러한 수요는 보다 효율적인 치료의 가능성, 유전체학의 발전, 질병의 복잡성, 규제의 뒷받침에 의해 촉진되고 있습니다. 길랭 바레 증후군(GBS)의 경우, 맞춤형 의료는 환자 개개인의 프로파일에 따라 치료를 조정하여 치료 결과를 개선하고 부작용을 줄이는 것을 목표로 하고 있습니다. 예를 들어, 미국 비영리단체인 개인맞춤의료연합(Personalized Medicine Coalition)의 보고서에 따르면, 2024년 2월 FDA는 희귀질환에 대한 16건의 신규 맞춤형 치료제를 승인했으며, 이는 2022년 6건에서 증가한 수치입니다. 이러한 추세는 맞춤형 의료에 대한 선호도가 높아지면서 길랭 바레 증후군 치료제 시장의 성장을 견인하고 있다는 것을 뒷받침합니다.

길랭 바레 증후군 치료제 시장의 주요 업체들은 시장에서의 입지를 유지하기 위해 인간화 단클론항체와 같은 제품을 개발하여 혁신을 추진하고 있습니다. 인간화 단클론항체는 인간 항체와 마우스나 쥐의 단클론항체 일부를 결합시켜 실험실에서 만들어지는 항체입니다. 인간화 단클론항체는 GBS 병태생리에 관여하는 특정 면역계 성분을 표적으로 삼을 수 있기 때문에 잠재적인 치료제로 검토되고 있습니다. 예를 들어, 2023년 10월 미국 바이오 제약사 아넥손은 ANX005가 유럽의약품청(EMA)과 FDA로부터 GBS 치료제로 희귀의약품 지정을 받았다고 발표했습니다. 초기 단계의 GBS에서 보체를 통한 염증과 신경세포 손상을 차단합니다. ANX005는 신경계에서 C1q 활성을 선택적으로 억제하여 염증과 신경 손상을 완화하고, GBS 환자의 자가면역질환을 조기에 멈추고 근력 회복을 촉진할 수 있도록 도와줄 것으로 기대됩니다. 자가면역 장애의 신속한 중단과 근력 회복을 촉진하는 것을 목표로 하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 신종 코로나바이러스 감염증, 그리고 경기회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 길랭 바레 증후군 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업 분석
• 세계의 길랭 바레 증후군 치료제 시장 : 성장률 분석
• 세계의 길랭 바레 증후군 치료제 시장 실적 : 규모와 성장, 2019-2024
• 세계의 길랭 바레 증후군 치료제 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 길랭 바레 증후군 치료제 전체 시장(TAM)

제6장 시장 세분화

• 세계의 길랭 바레 증후군 치료제 시장 : 약물 종류별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 면역글로불린(IVIG)
• 코르티코스테로이드
• 혈장 교환
• 세계의 길랭 바레 증후군 치료제 시장 : 치료 종류별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 1차 치료
• 보조적 또는 지지적인 치료
• 세계의 길랭 바레 증후군 치료제 시장 : 용도별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 클리닉
• 병원
• 기타 용도
• 세계의 길랭 바레 증후군 치료제 시장, 면역글로블린(IVIG) 하위 세분화(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 정맥내 면역글로불린(IVIG) 요법
• 인간 정상 면역글로불린(HNIG)
• 고도 면역글로불린 제제
• GBS 치료를 위한 IVIG 제제
• IVIG 치료 일환으로서의 단클론항체
• 세계의 길랭 바레 증후군 치료제 시장, 코르티코스테로이드 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 메틸프레드니솔론
• 프레드니솔론
• 덱사메타손
• 하이드로코르티손
• 베타메타손
• 경구 코르티코스테로이드 제제
• 세계의 길랭 바레 증후군 치료제 시장, 혈장 교환 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 치료적 혈장 교환(TPE)
• GBS 치료를 위한 혈장 교환 장비
• 원심 혈장 교환
• 면역흡착 혈장 교환
• 자가 혈장 교환(APE)

제7장 지역별·국가별 분석

• 세계의 길랭 바레 증후군 치료제 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 길랭 바레 증후군 치료제 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 길랭 바레 증후군 치료제 시장 : 경쟁 구도
• 길랭 바레 증후군 치료제 시장 : 기업 개요
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 주요 기업과 혁신적 기업

• Biogen Inc.
• Chugai Pharmaceutical Co. Ltd.
• Grifols SA
• Octapharma AG
• Cadila Healthcare Limited
• Argenx SE
• Alnylam Pharmaceuticals Inc.
• Biotest AG
• CSL Behring LLC
• Kedrion Biopharma Inc.
• Cellenkos Inc.
• Annexon Inc.
• Hansa Medical AB
• Akari Therapeutics Plc
• Alexion Pharmaceuticals Inc.

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 길랭 바레 증후군 치료제 시장 2029 : 새로운 기회를 제공하는 국가
• 길랭 바레 증후군 치료제 시장 2029 : 새로운 기회를 제공하는 부문
• 길랭 바레 증후군 치료제 시장 2029 : 성장 전략
  • 시장 동향에 기반한 전략
  • 경쟁 전략

제36장 부록

ksm

영문 목차

영문목차

Guillain-Barre syndrome drugs are medications designed to address the symptoms and complications associated with Guillain-Barre syndrome (GBS), an autoimmune condition characterized by the immune system attacking the nervous system. These drugs primarily target modulating the activity of the peripheral immune system to slow down the disease's progression and alleviate its symptoms.

The primary classes of Guillain-Barre syndrome drugs include immunoglobulins (IVIG), corticosteroids, and plasma exchange. Intravenous immunoglobulin (IVIG) is a medication derived from pooled human blood plasma containing a high concentration of antibodies. It is used as a first-line treatment and in adjunctive or supportive therapy, finding widespread use in clinics, hospitals, and other medical settings.

The Guillain-Barre syndrome drugs market research report is one of a series of new reports from The Business Research Company that provides Guillain-Barre syndrome drugs market statistics, including Guillain-Barre syndrome drugs industry global market size, regional shares, competitors with a Guillain-Barre syndrome drugs market share, detailed Guillain-Barre syndrome drugs market segments, market trends and opportunities, and any further data you may need to thrive in the Guillain-Barre syndrome drugs industry. This Guillain-Barre syndrome drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The guillain-barre syndrome drugs market size has grown strongly in recent years. It will grow from $1.17 billion in 2024 to $1.26 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to progress in the field of research and development, governmental programs and assistance with regulations, increased focus on neurology and autoimmune diseases, increased focus on reducing healthcare costs, and growth in demand for hospital and clinic services.

The guillain-barre syndrome drugs market size is expected to see strong growth in the next few years. It will grow to $1.71 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to the growing rate of guillain-barre syndrome (GBS) incidence, increasing recognition and recognition rates, growing geriatric population, increasing role of hospital pharmacies and retail pharmacies, and growing demand for oral and parenteral medications. Major trends in the forecast period include the development of new therapies, advancements in diagnostic tools, collaboration between pharmaceutical companies and research institutions, advancements in gene therapy, and advancements in intravenous immunoglobulin therapy.

The expected surge in demand for personalized medicine is set to drive growth in the Guillain-Barre syndrome drugs market. Personalized medicine involves customizing medical treatments based on individual characteristics such as genetics or lifestyle to optimize effectiveness and minimize side effects. This demand is fueled by the potential for more efficient treatments, advancements in genomics, the increasing complexity of diseases, and regulatory backing. In Guillain-Barre syndrome (GBS), personalized medicine aims to tailor treatments according to individual patient profiles, improving therapeutic outcomes and reducing adverse effects. For instance, in February 2024, the FDA approved 16 novel personalized therapies for rare diseases, up from six in 2022, as reported by the US-based non-profit organization, Personalized Medicine Coalition. This trend underscores how the rising preference for personalized medicine is pushing growth in the Guillain-Barre syndrome drugs market.

Key players in the guillain-barre syndrome drugs market are innovating by developing products such as humanized monoclonal antibodies to maintain their market presence. Humanized monoclonal antibodies are lab-made antibodies that combine human antibodies with parts of mouse or rat monoclonal antibodies. They are explored as potential therapies due to their ability to target specific immune system components involved in GBS pathology. For example, in October 2023, Annexon Inc., a US-based biopharmaceutical company, announced that ANX005 received orphan drug designation from the European Medicines Agency (EMA) and the FDA for GBS treatment. ANX005, a humanized monoclonal antibody, works by inhibiting C1q to halt complement-mediated inflammation and neuronal damage in early-stage GBS. Annexon has completed target enrollment in a Phase 3 trial of ANX005 in GBS, with top-line data expected in the first half of 2024. ANX005 aims to mitigate inflammation and nerve damage by selectively blocking C1q activity in the nervous system, promoting rapid cessation of autoimmune damage and muscle strength recovery in GBS patients.

In April 2022, Grifols SA, a Spanish pharmaceutical company, acquired Biotest AG for $1.17 billion, aiming to expand and diversify its plasma supply. This strategic move also strengthens Grifols' presence and revenues in Europe, the Middle East, and Africa, while fostering collaboration between Grifols and Biotest to improve global access to plasma-derived therapies. Biotest AG, based in Germany, provides drugs for Guillain-Barre syndrome (GBS) treatment.

Major companies operating in the guillain-barre syndrome drugs market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Grifols SA, Octapharma AG, Cadila Healthcare Limited, Argenx SE, Alnylam Pharmaceuticals Inc., Biotest AG, CSL Behring LLC, Kedrion Biopharma Inc., Cellenkos Inc., Annexon Inc., Hansa Medical AB, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc., Vitality Biopharma Inc., CuraVac Inc., Regenesance BV, Cresence AS, Shire Plc

North America was the largest region in the Guillain-Barre syndrome drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the guillain-barre syndrome drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the guillain-barre syndrome drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The Guillain-Barre syndrome drugs market consists of sales of monoclonal antibodies, cell therapies, and recombinant enzymes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Guillain-Barre Syndrome Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on guillain-barre syndrome drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for guillain-barre syndrome drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The guillain-barre syndrome drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Immunoglobulins (IVIG); Corticosteroids; Plasma Exchange
• 2) By Treatment Type: First-Line Treatment; Adjunctive Or Supportive Treatment
• 3) By Application: Clinic; Hospital; Other Applications
• Subsegments:
• 1) By Immunoglobulins (Ivig): Intravenous Immunoglobulin (Ivig) Therapy; Human Normal Immunoglobulin (Hnig); Hyperimmune Immunoglobulin Products; Ivig Formulations For Gbs Treatment; Monoclonal Antibodies As Part Of Ivig Treatment
• 2) By Corticosteroids: Methylprednisolone; Prednisolone; Dexamethasone; Hydrocortisone; Betamethasone; Oral Corticosteroid Formulations
• 3) By Plasma Exchange: Therapeutic Plasma Exchange (Tpe); Plasmapheresis Equipment For Gbs Treatment; Centrifugal Plasma Exchange; Immunoadsorption Plasma Exchange; Autologous Plasma Exchange (Ape)
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Novartis AG; Takeda Pharmaceutical Company Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Guillain-Barre Syndrome Drugs Market Characteristics

3. Guillain-Barre Syndrome Drugs Market Trends And Strategies

4. Guillain-Barre Syndrome Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Guillain-Barre Syndrome Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Guillain-Barre Syndrome Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Guillain-Barre Syndrome Drugs Market Growth Rate Analysis
• 5.4. Global Guillain-Barre Syndrome Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Guillain-Barre Syndrome Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Guillain-Barre Syndrome Drugs Total Addressable Market (TAM)

6. Guillain-Barre Syndrome Drugs Market Segmentation

• 6.1. Global Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunoglobulins (IVIG)
• Corticosteroids
• Plasma Exchange
• 6.2. Global Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• First-Line Treatment
• Adjunctive Or Supportive Treatment
• 6.3. Global Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinic
• Hospital
• Other Applications
• 6.4. Global Guillain-Barre Syndrome Drugs Market, Sub-Segmentation Of Immunoglobulins (IVIG), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous Immunoglobulin (IVIG) Therapy
• Human Normal Immunoglobulin (HNIG)
• Hyperimmune Immunoglobulin Products
• IVIG Formulations For GBS Treatment
• Monoclonal Antibodies As Part Of IVIG Treatment
• 6.5. Global Guillain-Barre Syndrome Drugs Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Methylprednisolone
• Prednisolone
• Dexamethasone
• Hydrocortisone
• Betamethasone
• Oral Corticosteroid Formulations
• 6.6. Global Guillain-Barre Syndrome Drugs Market, Sub-Segmentation Of Plasma Exchange, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Therapeutic Plasma Exchange (TPE)
• Plasmapheresis Equipment For GBS Treatment
• Centrifugal Plasma Exchange
• Immunoadsorption Plasma Exchange
• Autologous Plasma Exchange (APE)

7. Guillain-Barre Syndrome Drugs Market Regional And Country Analysis

• 7.1. Global Guillain-Barre Syndrome Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Guillain-Barre Syndrome Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Guillain-Barre Syndrome Drugs Market

• 8.1. Asia-Pacific Guillain-Barre Syndrome Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Guillain-Barre Syndrome Drugs Market

• 9.1. China Guillain-Barre Syndrome Drugs Market Overview
• 9.2. China Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Guillain-Barre Syndrome Drugs Market

• 10.1. India Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Guillain-Barre Syndrome Drugs Market

• 11.1. Japan Guillain-Barre Syndrome Drugs Market Overview
• 11.2. Japan Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Guillain-Barre Syndrome Drugs Market

• 12.1. Australia Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Guillain-Barre Syndrome Drugs Market

• 13.1. Indonesia Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Guillain-Barre Syndrome Drugs Market

• 14.1. South Korea Guillain-Barre Syndrome Drugs Market Overview
• 14.2. South Korea Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Guillain-Barre Syndrome Drugs Market

• 15.1. Western Europe Guillain-Barre Syndrome Drugs Market Overview
• 15.2. Western Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Guillain-Barre Syndrome Drugs Market

• 16.1. UK Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Guillain-Barre Syndrome Drugs Market

• 17.1. Germany Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Guillain-Barre Syndrome Drugs Market

• 18.1. France Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Guillain-Barre Syndrome Drugs Market

• 19.1. Italy Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Guillain-Barre Syndrome Drugs Market

• 20.1. Spain Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Guillain-Barre Syndrome Drugs Market

• 21.1. Eastern Europe Guillain-Barre Syndrome Drugs Market Overview
• 21.2. Eastern Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Guillain-Barre Syndrome Drugs Market

• 22.1. Russia Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Guillain-Barre Syndrome Drugs Market

• 23.1. North America Guillain-Barre Syndrome Drugs Market Overview
• 23.2. North America Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Guillain-Barre Syndrome Drugs Market

• 24.1. USA Guillain-Barre Syndrome Drugs Market Overview
• 24.2. USA Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Guillain-Barre Syndrome Drugs Market

• 25.1. Canada Guillain-Barre Syndrome Drugs Market Overview
• 25.2. Canada Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Guillain-Barre Syndrome Drugs Market

• 26.1. South America Guillain-Barre Syndrome Drugs Market Overview
• 26.2. South America Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Guillain-Barre Syndrome Drugs Market

• 27.1. Brazil Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Guillain-Barre Syndrome Drugs Market

• 28.1. Middle East Guillain-Barre Syndrome Drugs Market Overview
• 28.2. Middle East Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Guillain-Barre Syndrome Drugs Market

• 29.1. Africa Guillain-Barre Syndrome Drugs Market Overview
• 29.2. Africa Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Guillain-Barre Syndrome Drugs Market Competitive Landscape And Company Profiles

• 30.1. Guillain-Barre Syndrome Drugs Market Competitive Landscape
• 30.2. Guillain-Barre Syndrome Drugs Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

31. Guillain-Barre Syndrome Drugs Market Other Major And Innovative Companies

• 31.1. Biogen Inc.
• 31.2. Chugai Pharmaceutical Co. Ltd.
• 31.3. Grifols SA
• 31.4. Octapharma AG
• 31.5. Cadila Healthcare Limited
• 31.6. Argenx SE
• 31.7. Alnylam Pharmaceuticals Inc.
• 31.8. Biotest AG
• 31.9. CSL Behring LLC
• 31.10. Kedrion Biopharma Inc.
• 31.11. Cellenkos Inc.
• 31.12. Annexon Inc.
• 31.13. Hansa Medical AB
• 31.14. Akari Therapeutics Plc
• 31.15. Alexion Pharmaceuticals Inc.

32. Global Guillain-Barre Syndrome Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Guillain-Barre Syndrome Drugs Market

34. Recent Developments In The Guillain-Barre Syndrome Drugs Market

35. Guillain-Barre Syndrome Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Guillain-Barre Syndrome Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Guillain-Barre Syndrome Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Guillain-Barre Syndrome Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료